H. Eric Xu
徐华强
Founder and President of Cascade Pharmaceuticals Inc.
凯斯凯迪医药科技创始人，董事长
Dr. H. Eric Xu is a leading structural biologist. He has published more than 320 papers which have been cited over 44,000 times, including twenty in Nature and ten in Science. Two papers on plant hormone signaling were selected as one of the top ten breakthroughs by Science (2009) and by Chinese Academy of Sciences (2014). His X-ray laser structure of the first GPCR-arrestin complex was also selected as a top 10 breakthrough by Chinese Academy of Sciences in 2015 and was granted by the 2016 Hans Neurath Award of Protein Society and the 2016 Wuxi outstanding achievement award. He also has been awarded the Shanghai "Magnolia Memorial Award" and the 13th "C.C. Tan Life Science Achievement Award" in 2020 and 2021, respectively. In 2022, he won the 22th "Wu Jieping-Paul Janssen & Pharmaceutical Award" and the first prize of the ninth "Overseas Chinese Contribution Award". He also has been awarded the Shanghai "Magnolia Gold Award" in 2022. Most recently, he received the First Prize of the 2023 Shanghai Natural Science Award.
徐华强研究员主要从事激素受体结构与功能研究和药物研发。目前已发表SCI论文320余篇，其中在CELL, NATURE, SCIENCE主刊论文 40篇，引用次数超过44，000次，连续多年被评为“全球高被引学者”，并获得专利十余项。研究成果曾被《Science》杂志评为“2009年十大突破之一”、入选“2014年度中国科学十大进展”、入选两院院士评选“2015年中国十大科技进展新闻”、入选“2019年度中国医学重大进展（药学部）”、入选中国科学院上海分院2022和2023年度科技创新“十大进展”（基础研究类）和荣获“2023年度上海市自然科学奖一等奖”。徐华强研究员2016年荣获国际蛋白质学会Hans Neurath奖和“药明康德生命化学研究奖”杰出成就奖。2019、2021、2022、2023和2024年荣获中国科学院优秀导师奖。2020年荣获上海市“白玉兰纪念奖”。2021年荣获第十三届“谈家桢生命科学成就奖”。2022年荣获第二十二届“吴阶平-保罗杨森医学药学奖（吴杨奖）”。2022年荣获第九届“侨界贡献奖”一等奖。2022年荣获上海市“白玉兰荣誉奖”。2023年度上海市自然科学奖一等奖。
